<DOC>
	<DOCNO>NCT02802163</DOCNO>
	<brief_summary>The purpose study Phase l determine maximum tolerate dose panobinostat give combination carfilzomib , lenalidomide , dexamethasone 28-day cycle induction ( initial ) therapy participant newly diagnose multiple myeloma . In Phase , investigator evaluate safety ( side effect ) efficacy ( effectiveness ) panobinostat combination carfilzomib , lenalidomide , dexamethasone .</brief_summary>
	<brief_title>Induction Therapy Multiple Myeloma With Carfilzomib , Lenalidomide , Dexamethasone , Panobinostat</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Male female patient age ≥ 18 year old Ability provide write informed consent obtain prior participation study relate procedure perform Symptomatic multiple myeloma ( per IMWG diagnostic criterion ) prior treatment multiple myeloma Measurable disease least 1 follow assess within 21 day prior Cycle 1 Day 1 : . ) Serum Mprotein ≥ 0.5 g/d ; , b . ) Urine Mprotein ≥ 200 mg/24 hour ; c. ) In potential participant without detectable serum urine Mprotein , serum free light chain ( SFLC ) &gt; 100 mg/L ( involved light chain ) abnormal serum kappa lambda ratio . Must meet follow laboratory criterion within 21 day prior Cycle 1 , day 1 : . ) Absolute neutrophil count ( ANC ) ≥ 1 x 10^9/L ; b . ) Hemoglobin ≥ 8 g/dl ; c. ) Platelet count ≥ 75,000/mm^3 unless thrombocytopenia due marrow infiltration myeloma ; d. ) AST ALT ≤ 2.5 x upper limit normal ( ULN ) ; e. ) Serum bilirubin ≤ 1.5 x ULN ; f. ) Serum Creatinine clearance ≥ 50 ml/min . Baseline multiple uptake gated acquisition scan ( MUGA ) echocardiogram ( ECHO ) must demonstrate leave ventricular ejection fraction ( LVEF ) ≥ 45 % Females childbearing potential ( FCBP ) must negative serum pregnancy test within 10 14 day prior study drug administration negative urine pregnancy test within 24 hour prior first study drug administration male sexually active FCBP must agree use 2 highly effective concomitant method contraception include male condom study 90 day follow last dose study treatment Prior histone deacetylase ( HDAC ) , deacetylase ( DAC ) , HSP90 inhibitor valproic acid treatment cancer Potential participant need valproic acid medical condition study within 5 day prior first panobinostat treatment Impaired cardiac function clinically significant cardiac disease , include one following : History presence sustain ventricular tachyarrhythmia . ( Patients history atrial arrhythmia eligible discuss principal investigator prior enrollment ) ; Any history ventricular fibrillation torsade de pointes ; Bradycardia define HR &lt; 50 bpm . ( Patients pacemaker eligible heart rate ( HR ) ≥ 50 bpm . ) ; Screening ECG QTc &gt; 450 msec ; Right bundle branch block + leave anterior hemiblock ( bifascicular block ) ; Patients myocardial infarction unstable angina ≤ 12 month prior start study drug ; Other clinically significant heart disease ( e.g. , chronic heart failure ( CHF ) New York Heart Association class III IV , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption panobinostat Diarrhea &gt; NCI common terminology criterion adverse event ( CTCAE ) grade 2 Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) include abnormal laboratory value , could cause unacceptable safety risk compromise compliance protocol Using medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug Have receive prior treatment multiple myeloma exclude dexamethasone exceed 160 mg total Have receive radiation therapy &gt; 30 % marrowbearing bone within &lt; 2 week prior start study treatment ; yet recover side effect therapy . Have undergone major surgery ≤ 4 week prior start study drug recover side effect therapy Women pregnant breast feed woman childbearing potential ( WOCBP ) use effective method birth control . Women childbearing potential must negative serum pregnancy test within 24 hr receive first dose study medication . Males whose sexual partner WOCBP use effective birth control A prior malignancy last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) Known positivity human immunodeficiency virus ( HIV ) ) hepatitis C ; baseline test HIV hepatitis C require Any significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) Plasma cell leukemia ( &gt; 2.0 × 10^9/L circulate plasma cell standard differential ) Known history allergy Captisol ( cyclodextrin derivative use solubilize carfilzomib ) Contraindication require concomitant drug supportive treatment , include hypersensitivity antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>untreated multiple myeloma</keyword>
	<keyword>newly diagnose myeloma</keyword>
	<keyword>transplant eligible</keyword>
</DOC>